Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations

Código QR

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations

Masamichi Fukuda, Shinsuke Shibata, Naoko Shibata, Kenta Hagihara, Hiromoto Yaguchi, Hiromi Osada, Nobuo Takahashi, Eri Kubo, Hiroshi SasakiDepartment of Ophthalmology, Kanazawa Medical University, Uchinada, JapanPurpose: To investigate the safety of five types of antiglaucoma prostaglandin analog o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fukuda M, Shibata S, Shibata N, Hagihara K, Yaguchi H, Osada H, Takahashi N, Kubo E, Sasaki H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/3855b2f9298c4cd7a0932b2ee13b91da
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Corneal epithelial toxicity of antiglaucoma formulations: in vitro study of repeated applications
por: Meloni M, et al.
Publicado: (2012)

Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study.
por: Hong Liang, et al.
Publicado: (2012)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
por: Lo JS, et al.
Publicado: (2016)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: J Charles Henry, et al.
Publicado: (2008)

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
por: Schmier JK, et al.
Publicado: (2014)

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
por: Michael B Horsley, et al.
Publicado: (2009)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
por: Costa VP, et al.
Publicado: (2012)

Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis
por: Kazutaka Kamiya, et al.
Publicado: (2009)

Addition Of D-Sorbitol Improves The Usability Of Ophthalmic Viscosurgical Devices
por: Watanabe I, et al.
Publicado: (2019)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
por: Hommer A, et al.
Publicado: (2011)

First-year treatment costs among new initiators of topical prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2009)

Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2010)

Intraocular pressure dynamics with prostaglandin analogs: a clinical application of water-drinking test
por: Özyol P, et al.
Publicado: (2016)

Effect of prostaglandin analogs on matrix metalloproteinases and tissue inhibitor of metalloproteinases in eyelid muscle specimens
por: Karli S, et al.
Publicado: (2018)

Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles
por: Nagai N, et al.
Publicado: (2019)

Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity
por: Scott D, et al.
Publicado: (2011)

Clinical utility of antimicrobial susceptibility measurement plate covering formulated concentrations of various ophthalmic antimicrobial drugs
por: Tou N, et al.
Publicado: (2016)

First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
por: Jordana K Schmier, et al.
Publicado: (2010)

Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines
por: Masahiko Ayaki, et al.
Publicado: (2010)

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
por: Anne J Lee, et al.
Publicado: (2010)

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
por: Takagi Y, et al.
Publicado: (2018)

Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
por: Masahiko Ayaki, et al.
Publicado: (2010)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu Y, et al.
Publicado: (2015)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2011)

Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects
por: Pillunat LE, et al.
Publicado: (2011)

Prostaglandins

Prostaglandin-associated periorbitopathy in latanoprost users
por: Nakakura S, et al.
Publicado: (2014)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
por: Lorenz K, et al.
Publicado: (2011)

ON SOME FUNCTIONS CONCERNING FUZZY PG-CLOSED SETS
por: CALDAS,M, et al.
Publicado: (2006)

The analogies between human development and additive manufacture: Expanding the definition of design
por: L. E. J. Thomas-Seale, et al.
Publicado: (2019)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
por: Tamçelik N, et al.
Publicado: (2017)

Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
por: Halder A, et al.
Publicado: (2020)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
por: Inoue K, et al.
Publicado: (2012)

Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
por: Salehzadeh F, et al.
Publicado: (2019)

Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming
por: Naoto Muraoka, et al.
Publicado: (2019)

Successful treatment of prostaglandin-induced cystoid macular edema with subtenon triamcinolone
por: Matsuura K, et al.
Publicado: (2012)

Development of chloride-free oil with sulfur-based EP additive for cold forming of stainless steel
por: Tomohiro TAKAKI, et al.
Publicado: (2018)

In situ imaging reveals disparity between prostaglandin localization and abundance of prostaglandin synthases
por: Kyle D. Duncan, et al.
Publicado: (2021)

Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design
por: Hao JF, et al.
Publicado: (2011)

Prefilled syringes and usability of ophthalmic viscosurgical devices
por: Shiba T, et al.
Publicado: (2014)